AC
BLUE

Ascend Capital’s bluebird bio BLUE Stock Holding History

Ascend Capital’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-355
Closed -$555K – 149
2015
Q1 		$555K Buy
+355
New +$468K 0.02% 158
2014
Q4 		– Sell
-6,948
Closed -$3.23M – 163
2014
Q3 		$3.23M Buy
+6,948
New +$3.21M 0.1% 155
2014
Q2 		– Sell
-4,636
Closed -$1.37M – 174
2014
Q1 		$1.37M Buy
+4,636
New +$1.4M 0.04% 173

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Ascend Capital's BLUE Position: Q2 2015 in Review

Ascend Capital sold out of bluebird bio (BLUE) in Q2 2015, closing a stake of 355 shares — an estimated $555K sold.

Ascend Capital first reported a position in BLUE in Q1 2014 and held it in 3 quarters. The position peaked at $3.23M in Q3 2014. 235 funds tracked by Wall St. Rank hold BLUE as of Q2 2015.

  • Ascend Capital reported no remaining bluebird bio position as of Q2 2015 after selling out during the quarter.
  • Ascend Capital sold 355 bluebird bio shares in Q2 2015, an estimated $555K.
  • Ascend Capital first reported a position in bluebird bio in Q1 2014 and held it in 3 quarters.
  • Ascend Capital's bluebird bio position peaked at $3.23M in Q3 2014.
  • 235 funds tracked by Wall St. Rank held bluebird bio as of Q2 2015.

Based on Ascend Capital's 13F filing for Q2 2015, filed 13 Aug 2015.